Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

Post time 6 day(s) ago

journal：JAMA Dermatology

Authors：Andrew Blauvelt; Henrique D. Teixeira; Eric L. Simpson; Antonio Costanzo; Marjolein De Bruin-Weller; Sebastien Barbarot; Vimal H. Prajapati; Peter Lio; Xiaofei Hu; Tianshuang Wu; John Liu; Barry Ladizinski; Alvina D. Chu; Kilian Eyerich

Published date：2021-9-1

DOI：10.1001/jamadermatol.2021.3023

PDF link：https://jamanetwork.com/journals ... 721758666.55503.pdf

Article link：https://doi.org/10.1001/jamadermatol.2021.3023

Article Source：American Medical Association (AMA)。

Remark：

Post time 6 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[JAMA] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[JAMA] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis Copy